Recce Ltd has released a press release.
Appendix 4C and Commentary
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Positive Data for RECCE 327 in MRSA Burns Wound Infection
- Recce Completes Raising of $6.76 million
- Key Family 2 Patent Granted in Japan for RECCE Antibiotics
- Funding Update
- Appendix 4E - Preliminary Final Report
Later from Recce Pharmaceuticals
- Positive Data from RECCE 327 Antibiotic Safety Studies
- Positive Efficacy Data in Kidney/UTI infections animal model
- Half Yearly Report and Accounts
- First-in-Human Clinical Trial Progress Update
- Recce Signs Phase I Human Clinical Trial Agreement
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals